Overview

HEM1036 Phase 2 Study in Low Anterior Resection Syndrome

Status:
Not yet recruiting
Trial end date:
2024-01-04
Target enrollment:
Participant gender:
Summary
Double-blind, randomized, placebo controlled phase 2 study to explore the efficacy and safety of HEM1036 in the treatment of subjects with LARS
Phase:
Phase 2
Details
Lead Sponsor:
HEM Pharma Inc.
Collaborator:
Premier Research Group plc